SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01815008

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

PHARMACOGENOMICS OF ANTI-PLATELET RESPONSE - I

This clinical trial is examining the role of genetic polymorphism on the effect of clopidogrel (with or without aspirin) on platelet response in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.

NCT01815008 Platelet Aggregation Platelet Transcriptome Coronary Artery Disease
MeSH: Coronary Artery Disease
HPO: Coronary artery atherosclerosis

2 Interventions

Name: Clopidogrel

Description: Clopidogrel 75 mg daily

Type: Drug

Clopidogrel

Name: Aspirin

Description: Aspirin 81 mg daily

Type: Drug

Clo Clopidogrel


Primary Outcomes

Description: ADP-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined. Higher impedance represent higher platelet aggregation.

Measure: Difference in ADP-induced Platelet Aggregation

Time: at baseline and at 1 week

Secondary Outcomes

Description: Arachidonic Acid-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined

Measure: Difference in Arachidonic Acid-induced Platelet Aggregation

Time: At baseline and after 1-week

Description: Collagen-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined

Measure: Difference in Collagen-induced Platelet Aggregation

Time: At Baseline and at 1 week

Description: Platelet transcriptome will be examined before and after 1 week of therapy with clopidogrel and differences will be determined

Measure: Changes in Platelet Transcriptome With Clopidogrel

Time: At baseline and at 1 week

Purpose: Prevention

Single Group Assignment


There is one SNP

SNPs


1 rs12041331

Platelet Aggregation Platelet Transcriptome Coronary Artery Disease Coronary Artery Disease The main goal of this study is to explore the impact of the PEAR1 genetic variant (rs12041331) on responsiveness to clopidogrel.



HPO Nodes


HPO:
Coronary artery atherosclerosis
Genes 48
LMNA LDLRAP1 LDLR ACTA2 CYP7A1 FBN1 APOE APOB ESR1 MAT2A ABCA1 KCNJ5 ABCG8 MYH11 ZNF687 TGFB2 LMNA LMNA ELN LMNA LIPC PPARG LMNA FOXE3 SERPIND1 SMAD4 TGFBR2 SMPD1 MFAP5 ABCA1 APOB LMNA LOX SMAD3 MYH11 MYH11 LOX LMNA PCSK9 ACTA2 ABCG8 ZMPSTE24 TGFB3 PRKG1 TGFBR1 MYLK CEP19 ABCG5